Volume : 12, Issue : 04, April – 2025

Title:

OVERVIEW OF ANTI-ANGINAL DRUGS

Authors :

Ajip A. Rathod*, Ayan Khan, Aditi V. tikait, Swati P. Deshmukh

Abstract :

Angina pectoris, characterized by chest pain due to myocardial ischemia, is a common manifestation of coronary artery disease. Anti-anginal drugs are essential in managing this condition by improving oxygen delivery to the heart or reducing myocardial oxygen demand. These agents are broadly classified into nitrates, beta-blockers, calcium channel blockers, and newer agents like ranolazine, ivabradine, and nicorandil. Nitrates, such as nitroglycerin, provide rapid relief by vasodilation, whereas beta-blockers and calcium channel blockers help prevent angina by controlling heart rate and reducing afterload. Emerging therapies target metabolic pathways and offer options for patients with refractory angina. This overview highlights the pharmacological mechanisms, clinical uses, and advancements in anti-anginal drug therapy, emphasizing the importance of personalized treatment strategies to enhance patient outcome[1].

Cite This Article:

Please cite this article in press Ajip A. Rathod et al., Overview Of Anti-Anginal Drugs., Indo Am. J. P. Sci, 2025; 12(04).

Number of Downloads : 10

References:

1. European Society of Cardiology. Guidelines for the management of angina pectoris. Eur Heart J. 2019;40(1):1-32.
2. Heidenreich PA, Trogdon JG, Zimmerman L, et al. Meta-analysis of antianginal therapies: a systematic review of randomized controlled trials. J Am Coll Cardiol. 2010;55(21):2331-40.
3. Banning AP, Boulton DW. Review of pharmacological approaches to angina management. Heart. 2011;97(11):926-31.
4. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2007 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264-74.
5. Biondi-Zoccai G, et al. Calcium channel blockers: clinical applications. J Cardiovasc Med. 2009;10(6):423-30.
6. Fihn SD, Gardin JM, Abrams J, et al. ACC/AHA/ACP—ASIM 2000 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2002;39(6):1189-230.
7. McMurray JJ, Adamopoulos S. Ranolazine for chronic angina: a review. Eur Heart J. 2013;34(16):1230-8.
8. Scirica BM, et al. Ranolazine: a novel antianginal agent. Circulation. 2013;127(2):253-62.
9. Kotecha D, Flather MD. Long-acting nitrates in angina management. Am J Cardiol. 2010;105(8):1159-65.
10. Krumholz HM, et al. New approaches to angina treatment: the role of nicorandil and ivabradine. Am Heart J. 2015;170(6):1014-22.
11. Tripathi KD. Essentials of medical pharmacology. 7th ed. Jaypee Brothers Medical Publishers (P) Ltd; 2013. p. 539-44.
12. Alsabah AS. Antianginal drug [Internet]. 2019. Available from: https://www.researchgate.net/publication/344177596
13. Firth J. Nitrates in the management of angina: mechanisms and clinical applications. Heart. 2010;96(14):1087-92.
14. Gould L, Smits P. Mechanisms of action of nitrates in angina pectoris. Cardiovasc Drugs Ther. 2014;28(2):145-53.
15. Liu Y, Prasad A. Nitrates and nitric oxide in cardiovascular medicine: therapeutic uses and mechanisms. Clin Cardiol. 2016;39(6):349-55.
16. Packer M. Nitrates and their role in heart failure. Am J Cardiol. 2004;93(4A):10A-16A.
17. Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular events: a systematic review and meta-analysis. Circulation. 2019;139(4):452-453.
18. McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.
19. Fihn SD, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina and non-ST-elevation myocardial infarction. *J Am Coll Cardiol*. 2012;60(7):645-681.
20. Bangalore S, Stefanini GG, Bagur R, et al. Comparison of everolimus-eluting and paclitaxel-eluting stents in patients with acute coronary syndromes. J Am Coll Cardiol 2016; 68(11): 1235-1245.
21. Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Bioresorbable scaffolds vs. drug-eluting stents in patients with acute coronary syndromes. J Am Coll Cardiol 2019; 74(11): 1423-1433.
22. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J Am Coll Cardiol 2011; 58(24): e44-e122.